Presently Pending Claims

Language to be added has been **bolded and underlined**, while language to be deleted has been ~~**bolded and stricken-through**~~.

1. (Canceled)

2. (Previously presented) The method of claim 27 wherein R^a is R^{8a}-phenyl or R^8-naphthyl.

3. (Previously presented) The method of claim 2 wherein R^a is  , wherein R^{8a} is $-CF_3$, CF_3O- or halogen; or R^a is  wherein R^8 is C_1-C_6 alkoxy.

4. (Previously presented) The method of claim 27 wherein R^3 is hydrogen, (C_1-C_6) alkyl, R^8-phenyl, R^8-benzyl or R^8-pyridyl.

5. (Previously presented) The method of claim 27 wherein R^1 is hydrogen; R^6 is hydrogen or methyl; R^4 is methyl; and R^5 and R^7 are each hydrogen.

6. (Currently amended) The method of claim 27 wherein R^2 is **phenyl substituted with** R^9, R^{10}, **and** R^{11}~~**-phenyl**~~; **pyridyl substituted with** R^9, R^{10}, **and** R^{11}~~**-pyridyl; pyridyl N-oxide substituted with R^9, R^{10}, and R^{11}; or an N-oxide thereof;**~~ or **pyrimidyl substituted with** R^9, R^{10}, **and** R^{11}~~**-pyrimidyl**~~.

7. (Previously presented) The method of claim 6 wherein R^2 is selected from the group consisting of



wherein R^9 and R^{10} are selected from the group consisting of (C_1-C_6)alkyl, halogen, -OH and $-NH_2$.

8. (Previously presented) The method of claim 27 wherein the CCR5 compound is selected from the group consisting of those represented by the structural formula

































































wherein R, R^3, R^6 and R^2 are as defined in the following table:

R	R^3	R^6	R^2
		H	
		-CH3	
		H	
		H	
		H	
		H	
		-CH3	
		-CH3	
		-CH3	
		-CH3	
		-CH3	
		-CH3	

		H	
		H	
		-CH_3	
		-CH_3	
		-CH_3	
		-CH_3	
	H	-CH_3	
	H	-CH_3	
	H	-CH_3	
	H	-CH_3	
		-CH_3	
	H	H	
		H	
		-CH_3	

		H	
		-CH_3	
		H	
		H	
		H	
		H	
		-CH_3	
	H	-CH_3	
	H	-CH_3	
		-CH_2CH_3	
		-CH_2CH_3	
		-CH_2CH_3	
		-CH_3	
		-CH_3	



































































		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	
		$-CH_3$	

9-14. (Canceled)

15. (Currently amended) A method of treating solid organ transplant rejection, and graft v. host disease, ~~arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis,~~ comprising administering to a human in need of such treatment a

therapeutically effective amount of a CCR5 antagonist of the structural formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

R is R^8-phenyl, R^8-pyridyl, R^8-thiophenyl or R^8-naphthyl;

R^1 is hydrogen or C_1-C_6 alkyl;

R^2 is **phenyl substituted with** R^9, R^{10}, **and** R^{11}~~**-phenyl**~~; **6-membered heteroaryl substituted with** R^9, R^{10}, **and** R^{11}~~**-substituted 6-membered heteroaryl**~~; **6-membered heteroaryl N-oxide substituted with** R^9, R^{10}, **and** R^{11}~~**-substituted 6-membered heteroaryl N-oxide**~~; **5-membered heteroaryl substituted with** R^{12}, **and** R^{13}~~**-substituted 5-membered heteroaryl**~~; naphthyl; fluorenyl;

diphenylmethyl;  or  ;

R^3 is hydrogen, C_1-C_6 alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkyl(C_1-C_6)alkyl, R^8-phenyl, R^8-phenyl(C_1-C_6)alkyl, R^8-naphthyl, R^8-naphthyl(C_1-C_6)alkyl, R^8-heteroaryl or R^8-heteroaryl(C_1-C_6)alkyl;

R^4, R^5, R^7 and R^{13} are independently selected from the group consisting of hydrogen and (C_1-C_6)-alkyl;

R^6 is hydrogen, C_1-C_6 alkyl or C_2-C_6 alkenyl;

R^8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -CF_3, CF_3O-, $CH_3C(O)$-, -CN, CH_3SO_2-, CF_3SO_2-, R^{14}-phenyl, R^{14}-benzyl, $CH_3C(=NOCH_3)$, $CH_3C(=NOCH_2CH_3)$,  , -NH_2, -$NHCOCF_3$,

-NHCONH(C_1-C_6 alkyl), -NHCO(C_1-C_6 alkyl), -NHSO$_2$(C_1-C_6 alkyl), 5-membered heteroaryl and  , wherein X is –O-, -NH- or –N(CH_3)-;

R^9 and R^{10} are independently selected from the group consisting of (C_1-C_6)alkyl, halogen, -N$R^{17}R^{18}$, -OH, -CF_3, -OCH_3, -O-acyl, -OCF_3 and –Si(CH_3)$_3$;

R^{11} is R^9, hydrogen, phenyl, -NO_2, -CN, -CH_2F, -CHF_2, -CHO, -CH=NOR^{17}, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, -N(R^{17})CON$R^{18}R^{19}$, -NHCONH(chloro-(C_1-C_6)alkyl), -NHCONH((C_3-C_1)cycloalkyl(C_1-C_6)alkyl), -NHCO(C_1-C_6)alkyl, -$NHCOCF_3$, -NHSO$_2$N((C_1-C_6)alkyl)$_2$, -NHSO$_2$(C_1-C_6)alkyl, -N(SO$_2$$CF_3$)$_2$, -NHCO$_2$($C_1$-$C_6$)alkyl, C_3-C_{10} cycloalkyl, -SR^{20}, -SOR^{20}, -SO$_2$$R^{20}$, -SO$_2$NH($C_1$-$C_6$ alkyl), -OSO$_2$(C_1-C_6)alkyl, -OSO_2CF_3, hydroxy(C_1-C_6)alkyl, -CON $R^{17}R^{18}$, -CON(CH_2CH_2-O-CH_3)$_2$, -OCONH(C_1-C_6)alkyl, -CO$_2$$R^{17}$, –Si($CH_3$)$_3$ or –B(OC(CH_3)$_2$)$_2$;

R^{12} is (C_1-C_6)alkyl, -NH_2 or R^{14}-phenyl;

R^{14} is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, -CF_3, -CO$_2$$R_{17}$, -CN, ($C_1$-$C_6$)alkoxy and halogen;

R^{15} and R^{16} are independently selected from the group consisting of hydrogen and C_1-C_6 alkyl, or R^{15} and R^{16} together are a C_2-C_5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;

R^{17}, R^{18} and R^{19} are independently selected from the group consisting of H and C_1-C_6 alkyl; and

R^{20} is C_1-C_6 alkyl or phenyl.

16. (Original) The method of claim 15 wherein R is R^8-phenyl or R^8-naphthyl.

17. (Original) The method of claim 16 wherein R is  .

18. (Original) The method of claim 15 wherein R^3 is hydrogen, (C_1-C_6) alkyl, R^8-phenyl, R^8-benzyl or R^8-pyridyl.

19. (Original) The method of claim 15 wherein R^1 is hydrogen and R^6 is hydrogen or methyl.

20. (Currently amended) The method of claim 15 wherein R^2 is **phenyl substituted with** R^9, R^{10}, **and** R^{11} ~~**-phenyl**~~; **pyridyl substituted with** R^9, R^{10}, **and** R^{11} ~~**-pyridyl; or an**~~ **pyridyl** N-oxide **substituted with R^9, R^{10}, and R^{11};** ~~**thereof,**~~ or **pyrimidyl substituted with** R^9, R^{10}, **and** R^{11} ~~**-pyrimidyl**~~.

21. (Original) The method of claim 20 wherein R^2 is selected from the group consisting of


, 
, 
and 
,

wherein R^9 and R^{10} are selected from the group consisting of $(C_1\text{-}C_6)$alkyl, halogen, -OH and $-NH_2$.

22. (Currently amended) The method of claim 21 wherein R^2 is **selected from the group consisting of** ~~**phenyl or pyridyl and**~~


, 
, and 

wherein R^{11} is hydrogen~~,~~; ~~**or wherein R^2 is pyrimidyl**~~ and



wherein R^{11} is hydrogen, methyl or phenyl.

23-24. (Canceled)

25. (Currently amended) The method of claim 15~~,~~ ~~**for the treatment of solid organ transplant rejection, graft v. host disease, inflammatory bowel disease, rheumatoid arthritis or multiple sclerosis,**~~ further comprising **administering** one or more other agents useful in the treatment of said diseases.

26. (Canceled)

27. (Currently amended) A method treating solid organ transplant rejection, **and** graft v. host disease, ~~**inflammatory bowel disease, rheumatoid**~~

~~arthritis or multiple sclerosis~~ comprising administering to a human in need of such treatment a therapeutically effective amount of a CCR5 antagonist of the structural formula II



II

or a pharmaceutically acceptable salt thereof, wherein

(1) R^a is R^{8a}-phenyl, R^{8b}-pyridyl, R^{8b}-thiophenyl or R^8-naphthyl;

R^1 is hydrogen or C_1-C_6 alkyl;

R^2 is **phenyl substituted with** R^9, R^{10}, **and** R^{11}~~-phenyl~~; **6-membered heteroaryl substituted with** R^9, R^{10}, **and** R^{11}~~-substituted 6-membered heteroaryl~~; **6-membered heteroaryl N-oxide substituted with** R^9, R^{10}, **and** R^{11}~~-substituted 6-membered heteroaryl N-oxide~~; **5-membered heteroaryl substituted with** R^{12}, **and** R^{13}~~-substituted 5-membered heteroaryl~~; naphthyl; fluorenyl;

diphenylmethyl~~;~~  or  ;

R^3 is hydrogen, C_1-C_6 alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkyl(C_1-C_6)alkyl, R^8-phenyl, R^8-phenyl(C_1-C_6)alkyl, R^8-naphthyl, R^8-naphthyl(C_1-C_6)alkyl, R^8-heteroaryl or R^8-heteroaryl(C_1-C_6)alkyl;

R^4, R^5, R^7 and R^{13} are independently selected from the group consisting of hydrogen and (C_1-C_6)-alkyl;

R^6 is hydrogen, C_1-C_6 alkyl or C_2-C_6 alkenyl;

R^8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -CF_3, CF_3O-, $CH_3C(O)$-, -CN, CH_3SO_2-, CF_3SO_2-, R^{14}-phenyl, R^{14}-benzyl, $CH_3C(=NOCH_3)$, $CH_3C(=NOCH_2CH_3)$,  , -NH_2, -$NHCOCF_3$,

-NHCONH(C_1-C_6 alkyl), -NHCO(C_1-C_6 alkyl), -NHSO$_2$(C_1-C_6 alkyl), 5-membered heteroaryl and  , wherein X is –O-, -NH- or –N(CH_3)-;

R^{8a} is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, -CF_3, CF_3O-, -CN, CF_3SO_2-, R^{14}-phenyl, -NHCOCF_3, 5-membered heteroaryl and  , wherein X is as defined above;

R^{8b} is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, -CF_3, CF_3O-, $CH_3C(O)$-, -CN, CF_3SO_2-, R^{14}-benzyl, $CH_3C(=NOCH_3)$, $CH_3C(=NOCH_2CH_3)$,  , -NHCOCF_3, 5-membered heteroaryl and  , wherein X is as defined above;

R^9 and R^{10} are independently selected from the group consisting of (C_1-C_6)alkyl, halogen, -$NR^{17}R^{18}$, -OH, -CF_3, -OCH_3, -O-acyl, -OCF_3 and –Si(CH_3)$_3$;

R^{11} is R^9, hydrogen, phenyl, -NO_2, -CN, -CH_2F, -CHF_2, -CHO, -CH=NOR^{17}, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, -N(R^{17})C$ONR^{18}R^{19}$, -NHCONH(chloro-(C_1-C_6)alkyl), -NHCONH((C_3-C_1)cycloalkyl(C_1-C_6)alkyl), -NHCO(C_1-C_6)alkyl, -NHCOCF_3, -NHSO$_2$N((C_1-C_6)alkyl)$_2$, -NHSO$_2$(C_1-C_6)alkyl, -N(SO_2CF_3)$_2$, -NHCO$_2$(C_1-C_6)alkyl, C_3-C_{10} cycloalkyl, -SR^{20}, -SOR^{20}, -SO_2R^{20}, -SO$_2$NH(C_1-C_6 alkyl), -OSO$_2$(C_1-C_6)alkyl, -OSO_2CF_3, hydroxy(C_1-C_6)alkyl, -CON $R^{17}R^{18}$, -CON(CH_2CH_2-O-CH_3)$_2$, -OCONH(C_1-C_6)alkyl, -CO_2R^{17}, –Si(CH_3)$_3$ or –B(OC(CH_3)$_2$)$_2$;

R^{12} is (C_1-C_6)alkyl, -NH_2 or R^{14}-phenyl;

R^{14} is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, -CF_3, -CO_2R_{17}, -CN, (C_1-C_6)alkoxy and halogen;

R^{15} and R^{16} are independently selected from the group consisting of hydrogen and C_1-C_6 alkyl, or R^{15} and R^{16} together are a C_2-C_5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;

R^{17}, R^{18} and R^{19} are independently selected from the group consisting of H and C_1-C_6 alkyl; and

R^{20} is C_1-C_6 alkyl or phenyl; or

(2) R^a is R^8-phenyl, R^8-pyridyl or R^8-thiophenyl;

R^2 is fluorenyl, diphenylmethyl,  or  ;

and R^1, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19} and R^{20} are as defined in (1).

28-30. (Canceled)

31. (New) A method treating solid organ transplant rejection, and graft v. host disease, comprising administering to a human in need of such treatment a therapeutically effective amount of a CCR5 antagonist of the structural formula



or a pharmaceutically acceptable salt thereof.